Neurofibromatosis type 2–associated meningiomas: an international multicenter study of outcomes after Gamma Knife stereotactic radiosurgery

医学 放射外科 比例危险模型 2型神经纤维瘤病 累积发病率 脑膜瘤 放射科 回顾性队列研究 无进展生存期 神经纤维瘤病 肿瘤进展 放射治疗 外科 队列 内科学 癌症 总体生存率
作者
Nasser Mohammed,Yi-Chieh Hung,Zhiyuan Xu,Tomáš Chytka,Roman Liščák,Manjul Tripathi,David Arsanious,Christopher P. Cifarelli,Marco Pérez Cáceres,David Mathieu,Herwin Speckter,Gautam U. Mehta,Gregory P. Leković,Jason P. Sheehan
出处
期刊:Journal of Neurosurgery [American Association of Neurological Surgeons]
卷期号:136 (1): 109-114 被引量:6
标识
DOI:10.3171/2020.12.jns202814
摘要

OBJECTIVE The management of neurofibromatosis type 2 (NF2)–associated meningiomas is challenging. The role of Gamma Knife radiosurgery (GKRS) in the treatment of these tumors remains to be fully defined. In this study, the authors aimed to examine the role of GKRS in the treatment of NF2-associated meningiomas and to evaluate the outcomes and complications after treatment. METHODS Seven international medical centers contributed data for this retrospective cohort. Tumor progression was defined as a ≥ 20% increase from the baseline value. The clinical features, treatment details, outcomes, and complications were studied. The median follow-up was 8.5 years (range 0.6–25.5 years) from the time of initial GKRS. Shared frailty Cox regression was used for analysis. RESULTS A total of 204 meningiomas in 39 patients treated with GKRS were analyzed. Cox regression analysis showed that increasing the maximum dose (p = 0.02; HR 12.2, 95% CI 1.287–116.7) and a lower number of meningiomas at presentation (p = 0.03; HR 0.9, 95% CI 0.821–0.990) were predictive of better tumor control in both univariable and multivariable settings. Age at onset, sex, margin dose, location, and presence of neurological deficit were not predictive of tumor progression. The cumulative 10-year progression-free survival was 94.8%. Radiation-induced adverse effects were noted in 4 patients (10%); these were transient and managed medically. No post-GKRS malignant transformation was noted in 287 person-years of follow-up. CONCLUSIONS GKRS achieved effective tumor control with a low and generally acceptable rate of complications in NF2-associated meningiomas. There did not appear to be an appreciable risk of post–GKRS-induced malignancy in patients with NF2-treated meningiomas.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
西番雅完成签到,获得积分10
1秒前
风趣的亦巧完成签到,获得积分10
1秒前
诸沧海完成签到,获得积分10
2秒前
热狗完成签到 ,获得积分10
2秒前
武元彤完成签到,获得积分10
2秒前
Clovis33完成签到 ,获得积分10
2秒前
Yuanyuan发布了新的文献求助10
2秒前
何木萧完成签到,获得积分10
2秒前
赎罪完成签到 ,获得积分10
3秒前
3秒前
3秒前
xtz完成签到,获得积分10
3秒前
阿花阿花完成签到,获得积分10
3秒前
西番雅发布了新的文献求助10
4秒前
yating完成签到,获得积分10
4秒前
卷大喵完成签到,获得积分10
4秒前
Hephestus发布了新的文献求助10
4秒前
英姑应助黄俊采纳,获得10
5秒前
5秒前
体贴自行车完成签到 ,获得积分10
5秒前
7秒前
7秒前
赘婿应助追寻怜蕾采纳,获得10
7秒前
7秒前
一缕阳光完成签到,获得积分10
8秒前
9秒前
mgf发布了新的文献求助10
9秒前
QQWQEQRQ完成签到,获得积分10
9秒前
刘南发布了新的文献求助10
9秒前
kosmos完成签到,获得积分10
9秒前
ccc完成签到 ,获得积分10
9秒前
孙五六完成签到,获得积分10
10秒前
shuaishuyi完成签到,获得积分10
11秒前
想上985完成签到,获得积分10
11秒前
无私幻枫完成签到,获得积分10
11秒前
哈牛完成签到,获得积分10
12秒前
野性的傲珊完成签到,获得积分10
12秒前
奇尔韦尔发布了新的文献求助10
12秒前
gy发布了新的文献求助10
13秒前
耿丹彤发布了新的文献求助10
14秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
A new approach to the extrapolation of accelerated life test data 500
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3953707
求助须知:如何正确求助?哪些是违规求助? 3499536
关于积分的说明 11096135
捐赠科研通 3230090
什么是DOI,文献DOI怎么找? 1785865
邀请新用户注册赠送积分活动 869656
科研通“疑难数据库(出版商)”最低求助积分说明 801479